1. Absence of objectionable cognitive impairment or presence of dementia of severe degree defined by CDR score > 2.0. 
2. Unavailability of brain MRI (in case of absolute contraindications, the use of cranial CT is allowed). 
3. Expected poor compliance with the study protocol. 
4. Past diagnosis of major depression, schizophrenia, major anxiety syndrome, or manic- depressive illness. 
5. Diagnosis of degenerative cognitive impairment based on clinical and/or neuroradiological findings (i.e., patients with prevailing memory impairment, or with medial temporal atrophy on brain MRI in absence of evident vascular abnormalities; i.e., Alzheimer disease as defined using the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, Parkinson disease, Huntington disease, frontotemporal dementia). 
6. Diagnosis of cognitive impairment from other causes (i.e., vitamine B12 and folic acid deficiency, thyroid disorders, metabolic diseases, head trauma, tumor or infections of the central nervous system, normal pressure hydrocephalus). 
7. Medical conditions expected to progress, recur, or change to such a degree to interfere with the assessment of the clinical and mental status. 
8. Clinically relevant cardiac or pulmonary insufficiency. 
9. Relevant electrocardiograph abnormalities; bradycardia (50 bpm) or tachycardia (120 bpm) under resting conditions. 
10. Myocardial infarction within the past 6 months. 
11. Stroke still requiring neurological rehabilitation. 
12. Severe/untreated blood pressure (systolic 180 mm Hg, diastolic 95 mm Hg). 
13. Clinically relevant liver function impairment. 
14. Insulin-dependent diabetes mellitus. 
15. Idiopathic epilepsy and anti-epileptic treatment. 
16. Severe anemia (Hb <10 mg/dL). 
17. Severe gastrointestinal disease. 
18. Cancer. 
19. Known intolerance to study drugs. 
20. Coexistent serious illnesses that would imply a drop-out before the end of the trial.       
    

NCT03228498_exc_T22
Condition
cognitive impairment
NCT03228498_exc_T23
Qualifier
objectionable
NCT03228498_exc_T24
Negation
Absence
NCT03228498_exc_T25
Condition
dementia
NCT03228498_exc_T26
Qualifier
severe degree
NCT03228498_exc_T27
Measurement
CDR score
NCT03228498_exc_T28
Value
> 2.0
NCT03228498_exc_T29
Scope
objectionable cognitive impairment or presence of dementia of severe degree defined by CDR score > 2.0
NCT03228498_exc_T30
Procedure
brain MRI
NCT03228498_exc_T31
Negation
Unavailability
NCT03228498_exc_T32
Observation
Unavailability
NCT03228498_exc_T34
Procedure
cranial CT
NCT03228498_exc_T35
Condition
absolute contraindications
NCT03228498_exc_T38
Condition
major depression
NCT03228498_exc_T39
Condition
schizophrenia
NCT03228498_exc_T40
Condition
major anxiety syndrome
NCT03228498_exc_T41
Condition
manic- depressive illness
NCT03228498_exc_T42
Observation
Past diagnosis
NCT03228498_exc_T43
Scope
major depression, schizophrenia, major anxiety syndrome, or manic- depressive illness
NCT03228498_exc_T44
Condition
degenerative cognitive impairment
NCT03228498_exc_T46
Condition
clinical and/or neuroradiological findings
NCT03228498_exc_T48
Condition
memory impairment
NCT03228498_exc_T49
Condition
medial temporal atrophy
NCT03228498_exc_T50
Procedure
brain MRI
NCT03228498_exc_T51
Negation
absence
NCT03228498_exc_T52
Condition
vascular abnormalities
NCT03228498_exc_T54
Condition
Alzheimer disease
NCT03228498_exc_T55
Measurement
National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria
NCT03228498_exc_T56
Condition
Parkinson disease
NCT03228498_exc_T57
Condition
Huntington disease
NCT03228498_exc_T58
Condition
frontotemporal dementia
NCT03228498_exc_T59
Scope
memory impairment, or with medial temporal atrophy on brain MRI
NCT03228498_exc_T60
Scope
memory impairment, or with medial temporal atrophy on brain MRI in absence of evident vascular abnormalities
NCT03228498_exc_T61
Scope
Alzheimer disease as defined using the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, Parkinson disease, Huntington disease, frontotemporal dementia
NCT03228498_exc_T62
Scope
memory impairment, or with medial temporal atrophy on brain MRI in absence of evident vascular abnormalities; i.e., Alzheimer disease as defined using the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, Parkinson disease, Huntington disease, frontotemporal dementia
NCT03228498_exc_T63
Condition
cognitive impairment
NCT03228498_exc_T64
Qualifier
other causes
NCT03228498_exc_T65
Condition
vitamine B12 deficiency
NCT03228498_exc_T66
Condition
folic acid deficiency
NCT03228498_exc_T67
Condition
thyroid disorders
NCT03228498_exc_T68
Condition
metabolic diseases
NCT03228498_exc_T69
Condition
head trauma
NCT03228498_exc_T70
Condition
tumor of the central nervous system
NCT03228498_exc_T71
Condition
infections of the central nervous system
NCT03228498_exc_T72
Condition
normal pressure hydrocephalus
NCT03228498_exc_T73
Scope
vitamine B12 and folic acid deficiency, thyroid disorders, metabolic diseases, head trauma, tumor or infections of the central nervous system, normal pressure hydrocephalus
NCT03228498_exc_T78
Condition
cardiac insufficiency
NCT03228498_exc_T79
Condition
pulmonary insufficiency
NCT03228498_exc_T80
Qualifier
Clinically relevant
NCT03228498_exc_T81
Scope
cardiac or pulmonary insufficiency
NCT03228498_exc_T82
Condition
abnormalities
NCT03228498_exc_T83
Procedure
electrocardiograph
NCT03228498_exc_T84
Condition
bradycardia
NCT03228498_exc_T85
Measurement
50 bpm
NCT03228498_exc_T86
Condition
tachycardia
NCT03228498_exc_T87
Measurement
120 bpm
NCT03228498_exc_T88
Qualifier
under resting conditions
NCT03228498_exc_T89
Scope
bradycardia (50 bpm) or tachycardia (120 bpm)
NCT03228498_exc_T90
Scope
bradycardia (50 bpm) or tachycardia (120 bpm) under resting conditions
NCT03228498_exc_T91
Qualifier
Relevant
NCT03228498_exc_T93
Condition
Myocardial infarction
NCT03228498_exc_T94
Temporal
within the past 6 months
NCT03228498_exc_T95
Procedure
neurological rehabilitation
NCT03228498_exc_T96
Condition
Stroke
NCT03228498_exc_T99
Qualifier
requiring
NCT03228498_exc_T101
Measurement
systolic
NCT03228498_exc_T102
Measurement
diastolic
NCT03228498_exc_T103
Value
180 mm Hg
NCT03228498_exc_T104
Value
95 mm Hg
NCT03228498_exc_T105
Scope
systolic 180 mm Hg, diastolic 95 mm Hg
NCT03228498_exc_T106
Measurement
blood pressure
NCT03228498_exc_T107
Qualifier
Severe
NCT03228498_exc_T108
Qualifier
untreated
NCT03228498_exc_T109
Scope
Severe/untreated
NCT03228498_exc_T110
Condition
liver function impairment
NCT03228498_exc_T113
Qualifier
Clinically relevant
NCT03228498_exc_T114
Condition
Insulin-dependent diabetes mellitus
NCT03228498_exc_T115
Condition
Idiopathic epilepsy
NCT03228498_exc_T116
Condition
anti-epileptic treatment
NCT03228498_exc_T117
Condition
anemia
NCT03228498_exc_T118
Qualifier
Severe
NCT03228498_exc_T119
Measurement
Hb
NCT03228498_exc_T120
Value
<10 mg/dL
NCT03228498_exc_T121
Condition
gastrointestinal disease
NCT03228498_exc_T122
Qualifier
Severe
NCT03228498_exc_T125
Condition
Cancer
NCT03228498_exc_T126
Condition
intolerance
NCT03228498_exc_T127
Drug
study drugs